What makes the new oral vaccine superior to traditional injections for young fish?

Question

Accepted Answer

The new oral vaccine offers significant advantages over traditional injectable methods for young fish by enabling easier administration and critical early-stage protection against deadly viruses.

A novel oral vaccine developed by researchers at the National University of Singapore (NUS) presents a breakthrough for aquaculture by allowing vaccination through feed. This method is particularly advantageous for larvae and fingerlings, which are too small for individual injection. Traditional vaccination relies on injecting each fish one by one, a process that is both impractical for very young fish and extremely labour-intensive when dealing with large populations. The development addresses the critical need for early protection against viruses like the nervous necrosis virus, which can cause near-total mortality in infected larvae.
Simplified Administration for Vulnerable Fish

The primary benefit of the oral vaccine lies in its ease of administration, especially for juvenile fish. Unlike conventional methods that require individual handling and injection, this new approach integrates the vaccine directly into the fish's feed. This bypasses the physical challenges and stress associated with injecting small, delicate larvae and fingerlings. The practical implication is a more scalable and less demanding vaccination process, crucial for the economic viability of aquaculture operations that depend on high survival rates from the earliest life stages.
Critical Early-Stage Protection Against High Mortality Viruses

The oral vaccine is specifically designed to combat highly contagious and lethal viruses, such as the nervous necrosis virus, which poses a significant threat to aquaculture. This virus attacks the nervous system of fish, leading to devastating losses, with larvae facing almost 100% mortality when infected. By enabling vaccination at an early stage, the oral vaccine provides essential immunity before significant exposure occurs. This early protection is vital for increasing survival rates in commercially farmed species, thereby safeguarding the industry from substantial economic damage caused by such outbreaks.
Mechanism of Induced Immunity

The oral vaccine functions by utilising virus-like particles that mimic the structure of the actual pathogen without containing any infectious genetic material. These particles are encapsulated within Lactococcus lactis, a bacterium that shields them from stomach acid and facilitates their delivery to the fish's intestines. Upon absorption, the fish's immune system is stimulated to produce antibodies. These antibodies are capable of recognising and neutralising the virus, preventing it from infecting cells. This process effectively primes the fish's immune system to mount a rapid defence upon encountering the real virus.
Promising Efficacy in Trials

Preliminary trials, conducted under laboratory conditions on widely farmed species like Asian sea bass and grouper, have demonstrated the vaccine's potential. In grouper trials, vaccinated fish exhibited survival rates of approximately 95%, significantly higher than the 60% survival rate observed in unvaccinated control groups. While the oral vaccine, in its current form, may be less potent than injectable counterparts and requires higher doses for comparable protection, its ease of use for young fish represents a substantial advancement. The researchers have patented this technology and are actively seeking industry partnerships to conduct field trials on commercial farms.

Reading history

Hide →

This history is cleared when the page is closed.

What makes the new oral vaccine superior to traditional injections for young fish?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends